Epigral Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Press Release for Audited Financial Results Q4 & FY2025".
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral Limited (formerly Meghmani Finechem) posted its highest-ever annual revenue of ₹2,565 crore in FY2025, up 33% year-on-year, driven by 11% volume growth led by Derivatives & Specialty products. FY2025 PAT jumped 82% to ₹357 crore, with EBITDA up 48% to ₹711 crore and EBITDA margin expanding to 28% from 25%. In Q4FY25, revenue grew 20% to ₹631 crore, EBITDA rose 12% to ₹173 crore, and PAT was up 13% at ₹87 crore. The balance sheet strengthened with ROCE improving to 25% (from 18%) and Net Debt/EBITDA falling sharply to 0.7x (from 2.0x). Credit rating was upgraded to Crisil AA from AA-, the company raised ₹333 crore via QIP, spent ₹195 crore on capex, and announced doubling of CPVC Resin and Epichlorohydrin capacities. Total dividend for FY25 is ₹6 per share (60% on face value of ₹10).
Strong all-round results with broad-based revenue and profit growth, expanding margins, deleveraging, and a credit rating upgrade signal robust financial health. Capacity expansion, QIP proceeds, and higher dividend are positive for shareholders, though realizations dipped for most products in FY25.